iDose TR will help reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Credit: Sofie Zbořilová from Pixabay.

Speciality materials and chemical company Celanese has agreed with ophthalmic medical device company Glaukos for the supply of its VitalDose drug delivery platform.

Glaukos will use the VitalDose platform as a component in a micro-invasive intraocular implant, dubbed iDose TR, which will help reduce intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The integration of the VitalDose platform is expected to enable the delivery of continuous dosing, which can tackle the problem of patient non-adherence issues.

Celanese ophthalmology global business strategy leader Cyonna Holmes said: “The inclusion of our VitalDose Platform in Glaukos’ iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases.

“Our team is excited to support Glaukos as they continue to advance their efforts to bring iDose TR to patients who may need a new glaucoma treatment alternative.”

See Also:

Celanese offers the VitalDose EVA technology platform for use in various applications, including parenteral, ocular delivery, subcutaneous drug delivery implant, as well as ophthalmic, intravitreal and intraocular.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In February this year, Glaukos submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for iDose TR.

The NDA submission is based on results from two Phase II pivotal clinical studies, which assessed iDose TR.

Both studies achieved the primary efficacy endpoints within three months and showed favourable safety and tolerability profiles over 12 months.